OQROGet OQRO Pro
Insider trade

Inmed Pharmaceuticals (INM)10% owner bought ~$2.2K

Vivo Opportunity, 10% owner at Inmed Pharmaceuticals, bought ~$2.2K of Inmed Pharmaceuticals shares.

~$2.2K
Approx. value · 1,389 sh @ $1.55
75K
Holds after · shares reported
Traded
Jul 15, 2026
Filed
Jul 17, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. May 18, 2026Company filing · Form 8-K · Material agreement, Shareholder rightsSigned an important agreement, and changed the rights of its shareholders (and 1 more item)
  2. May 19, 2026Company filing · Form 8-K · Material agreement, Change of controlControl of the company changed hands, and changed a top executive or board member (and 2 more items)“On May 19, 2026, the Company and Mentari issued a joint press release announcing the entry into the Merger Agreement. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference, except that the information contained on the websites referenced in the press release is not incorporated herein by reference.”
  3. May 19, 2026Insider · 1 personInsiders: 3 purchases (~$722K)
  4. May 20, 2026Insider · 1 personInsiders: 2 purchases (~$88K)
  5. May 21, 2026Insider · 1 personInsiders: 2 purchases (~$57K)
  6. May 29, 2026Insider · 1 personInsiders: 2 purchases (~$28K)
  7. Jun 1, 2026Insider · 1 personInsiders: 2 purchases (~$25K)
  8. Jun 2, 2026Insider · 1 personInsiders: 2 purchases (~$35K)
  9. Jun 3, 2026Insider · 1 personInsiders: 2 purchases (~$12K)
  10. Jun 4, 2026Insider · 1 personInsiders: 2 purchases (~$11K)
  11. Jun 5, 2026Insider · 1 personInsiders: 2 purchases (~$86K)
  12. Jun 8, 2026Insider · 1 personInsiders: 2 purchases (~$49K)
  13. Jun 30, 2026Insider · 1 personInsiders: 2 purchases (~$924)
  14. Jul 1, 2026Insider · 1 personInsiders: 2 purchases (~$7K)
  15. Jul 2, 2026Insider · 1 personInsiders: 2 purchases (~$2K)
  16. Jul 6, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors
  17. Jul 14, 2026Insider · 1 personInsiders: 2 purchases (~$8K)
  18. Jul 15, 2026 · this disclosureInsider10% owner purchased ~$2.2K of INM shares in the open market

What came next

  1. Jul 15, 2026Insider · 2 peopleInsiders: 2 purchases (~$23K)
  2. Jul 16, 2026Insider · 1 personInsiders: 2 purchases (~$33)
  3. Sep 14, 2026Insider · 2 days before an 8-K10% owner purchased ~$37K of INM shares in the open market
  4. Sep 15, 2026Insider · 1 day before an 8-K10% owner purchased ~$70K of INM shares in the open market
  5. Sep 16, 2026Company filing · Form 8-K · Listing notice, Other newsReceived a notice from its stock exchange, and reported other company news“On September 16, 2026, InMed Pharmaceuticals Inc. (the "Company") received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying it that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in shareholders’ equity for continued listing.”
  6. Sep 16, 2026Insider10% owner purchased ~$11K of INM shares in the open market
  7. Oct 1, 2026Insider10% owner purchased ~$22K of INM shares in the open market
  8. Oct 2, 2026Insider10% owner purchased ~$11K of INM shares in the open market
  9. Oct 5, 2026Insider10% owner purchased ~$24K of INM shares in the open market
  10. Oct 6, 2026Insider10% owner purchased ~$7.4K of INM shares in the open market
  11. Oct 7, 20265% stakeADAR1 Capital Management, LLC reported a passive stake (13G) of 17.2%
  12. Oct 7, 2026Insider10% owner purchased ~$4.1K of INM shares in the open market
  13. Oct 8, 2026Insider10% owner purchased ~$3K of INM shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Inmed Pharmaceuticals

For Inmed Pharmaceuticals, OQRO holds 16 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its INM page.

Other recent filings by Vivo Opportunity, LLC, 10% owner

The full history of Vivo Opportunity, LLC, 10% owner is on the profile page.

How this filing works

Other disclosures at Inmed Pharmaceuticals

Everything OQRO holds on this company is on its INM page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data